+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 64Years
All Genders
ID07216027

Evaluating the Safety and Effectiveness of PF-08049820 Taken Orally for Moderate to Severe Atopic Dermatitis in Adults

Led by Pfizer · Updated on 2026-10-13

165

Participants Needed

42

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a study medicine called PF-08049820 for treating atopic dermatitis AD, also known as eczema, which can cause severe itching and skin rashes. This phase 2 randomized study involves adults aged 18 to 64 years who have had moderate to severe AD for at least six months and currently lack suitable prescribed treatments. Participants will take either PF-08049820 or a placebo tablet daily by mouth for 12 weeks during two stages of the study. Clinic visits are scheduled on Day 1, Weeks 1, 2, 4, 6, 8, and 12, followed by a follow-up visit at Week 16. The placebo looks like the study medicine but contains no active drug. The study compares the experiences of those receiving PF-08049820 to those on placebo to assess its safety and effects. During the study, participants will have their skin condition and overall health monitored through exams, blood and urine tests, and questionnaires about their symptoms and quality of life. Researchers will measure changes in the severity of eczema using tools like the Eczema Area and Severity Index EASI, along with other assessments of skin improvement and itching. Safety will be closely watched through reports of side effects, lab tests, and vital signs throughout the 16 weeks of participation.

CONDITIONS

Brief Title

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here